Disorders that affect the oral mucosa are very common irrespective of age, gender and demographics, and remain a constant challenge to treat. These disorders can be caused due to immune-dysregulation or immune-related pathophysiologies. In addition, they can arise because of infections, sustained trauma, chewing tobacco and related products, smoking, co-morbid conditions, alcohol use, and poor oral hygiene. Symptoms of oral mucosal diseases include erosions, erythema, red/ white patches, and other changes occurring on the gingiva, tongue, buccal region, lips, and the palate. These diseases are largely chronic, painful, and severe. They greatly impair day-to-day activities including eating, swallowing, and talking, which in turn affects the quality of life of the affected individual. Oral mucosal disorders are currently managed by the systemic or topical administration of steroids. However, long-term use of the current treatment modalities is associated with severe side effects and irreversible toxicities.
A reduction in the rate of discovery of new molecules has resulted in fewer innovations being developed for the treatment of oral mucosal disorders. Further research is required to find alternative and effective treatments. Furthermore, it is important to emphasize the variety of diseases occurring within the oral cavity, the possible pathways involved, and the ways a drug can effectively target these pathways for pharmacological effect. In this research topic, we aim to explore and collate experimental evidence for various alternatives in future research and development of oral mucosa disorders and treatment.
We welcome research on innovative approaches, technological advancements, and novel drug interventions catering to the unmet need in the treatment of oral mucosal disorders. Overall, the collection will present a unique perspective on the lesser explored immune-mediated diseases of the oral cavity and the mucosal tissues to open up new avenues for drug discovery and development.
The research topic welcomes the submissions of original research, systematic reviews, reviews and mini-reviews, clinical trials, and case reports pertaining to any oral mucosal disorder. The topics of interest include, but are not limited to, drug discovery, novel formulations and treatment modalities, their efficacy and performance testing in the areas of oral lichen planus, pemphigus and pemphigoids, aphthous ulcers, and oral submucous fibrosis, burning mouth syndrome (glossodynia), gingivostomatitis, oral cancer, and any other related mucosal disorders.
Disorders that affect the oral mucosa are very common irrespective of age, gender and demographics, and remain a constant challenge to treat. These disorders can be caused due to immune-dysregulation or immune-related pathophysiologies. In addition, they can arise because of infections, sustained trauma, chewing tobacco and related products, smoking, co-morbid conditions, alcohol use, and poor oral hygiene. Symptoms of oral mucosal diseases include erosions, erythema, red/ white patches, and other changes occurring on the gingiva, tongue, buccal region, lips, and the palate. These diseases are largely chronic, painful, and severe. They greatly impair day-to-day activities including eating, swallowing, and talking, which in turn affects the quality of life of the affected individual. Oral mucosal disorders are currently managed by the systemic or topical administration of steroids. However, long-term use of the current treatment modalities is associated with severe side effects and irreversible toxicities.
A reduction in the rate of discovery of new molecules has resulted in fewer innovations being developed for the treatment of oral mucosal disorders. Further research is required to find alternative and effective treatments. Furthermore, it is important to emphasize the variety of diseases occurring within the oral cavity, the possible pathways involved, and the ways a drug can effectively target these pathways for pharmacological effect. In this research topic, we aim to explore and collate experimental evidence for various alternatives in future research and development of oral mucosa disorders and treatment.
We welcome research on innovative approaches, technological advancements, and novel drug interventions catering to the unmet need in the treatment of oral mucosal disorders. Overall, the collection will present a unique perspective on the lesser explored immune-mediated diseases of the oral cavity and the mucosal tissues to open up new avenues for drug discovery and development.
The research topic welcomes the submissions of original research, systematic reviews, reviews and mini-reviews, clinical trials, and case reports pertaining to any oral mucosal disorder. The topics of interest include, but are not limited to, drug discovery, novel formulations and treatment modalities, their efficacy and performance testing in the areas of oral lichen planus, pemphigus and pemphigoids, aphthous ulcers, and oral submucous fibrosis, burning mouth syndrome (glossodynia), gingivostomatitis, oral cancer, and any other related mucosal disorders.
